The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SITC 2022 | TAP2 downregulation enables immune evasion in NSCLC tumors
Kishu Ranjan, PhD, Yale School of Medicine, New Haven, CT, discusses the role of TAP2 downregulation as a negative predictor of PD-L1 inhibitors in patients with non-small cell lung cancer (NSCLC). TAP2 is associated with transporting antigens from the cytoplasm to the endoplasmic reticulum and in an analysis of patients with NSCLC, lower TAP2 expression is associated with immune evasion and lower PD-L1 inhibitor efficacy. Novel compounds that can regulate TAP1 are being investigated to restore TAP2 expression. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
